On Jun. 25, 2024, Evotec announced that its Seattle-based subsidiary, Just – Evotec Biologics, was selected by the U.S. Department of Defense (DOD) to develop an accelerated monoclonal antibody (“mAb”) development and manufacturing solution for the DOD’s Manufacturing Optimization Program.

The multi-year program award, valued up to $ 39 million, will support the U.S. Government’s effort to enhance its rapid response capabilities for biologics medical countermeasures.